MX9604434A - Productos farmaceuticos y medicamentos para la prevencion y el tratamiento de disfunciones endoteliales. - Google Patents

Productos farmaceuticos y medicamentos para la prevencion y el tratamiento de disfunciones endoteliales.

Info

Publication number
MX9604434A
MX9604434A MX9604434A MX9604434A MX9604434A MX 9604434 A MX9604434 A MX 9604434A MX 9604434 A MX9604434 A MX 9604434A MX 9604434 A MX9604434 A MX 9604434A MX 9604434 A MX9604434 A MX 9604434A
Authority
MX
Mexico
Prior art keywords
medicaments
prevention
treatment
pharmaceutical preparations
endothelial dysfunction
Prior art date
Application number
MX9604434A
Other languages
English (en)
Inventor
Eike Noack
Georg Albrecht Koida
Original Assignee
Isis Pharma Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Isis Pharma Gmbh filed Critical Isis Pharma Gmbh
Publication of MX9604434A publication Critical patent/MX9604434A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4406—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 3, e.g. zimeldine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/556—Angiotensin converting enzyme inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Emergency Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invencion describe la utilizacion de compuestos liberadores o transmisores de monoxido de nitrogeno, de estimuladores de la formacion endogena de nonoxido de nitrogeno, así como de estimuladores de la guanilatociclasa para la prevencion, el tratamiento y la correccion de disfunciones enodteliales y de enfermedades que van acompañadas de dichas disfunciones o que son ocasionadas por las mismas, así como la utilizacion de los mencionadas compuestos para la fabricacion de productos farmacéuticos para los campos de aplicacion mencionados.
MX9604434A 1994-03-30 1995-03-28 Productos farmaceuticos y medicamentos para la prevencion y el tratamiento de disfunciones endoteliales. MX9604434A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE4410997A DE4410997A1 (de) 1994-03-30 1994-03-30 Pharmazeutische Zubereitungen und Arzneistoffe zur Prävention und Behandlung endothelialer Dysfunktionen
PCT/DE1995/000421 WO1995026725A1 (de) 1994-03-30 1995-03-28 Pharmazeutische zubereitingen und arzneistoffe zur prävention und behandlung endothelialer dysfunktion

Publications (1)

Publication Number Publication Date
MX9604434A true MX9604434A (es) 1997-12-31

Family

ID=6514213

Family Applications (1)

Application Number Title Priority Date Filing Date
MX9604434A MX9604434A (es) 1994-03-30 1995-03-28 Productos farmaceuticos y medicamentos para la prevencion y el tratamiento de disfunciones endoteliales.

Country Status (19)

Country Link
EP (1) EP0752858A1 (es)
JP (1) JPH09510979A (es)
CN (1) CN1150387A (es)
BG (1) BG63073B1 (es)
CA (1) CA2186783A1 (es)
CZ (1) CZ283696A3 (es)
DE (2) DE4410997A1 (es)
EE (1) EE9600139A (es)
FI (1) FI963883A (es)
HU (1) HU220165B (es)
IS (1) IS4365A (es)
LT (1) LT4310B (es)
LV (1) LV11666B (es)
MX (1) MX9604434A (es)
NO (1) NO964102D0 (es)
PL (1) PL316528A1 (es)
SI (1) SI9520047A (es)
SK (1) SK121896A3 (es)
WO (1) WO1995026725A1 (es)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9423868D0 (en) * 1994-11-25 1995-01-11 Wellcome Found Compounds for use in medicine
DE19654895C2 (de) * 1996-02-07 2000-07-27 Sanol Arznei Schwarz Gmbh Detektionsverfahren
DE19604361C2 (de) * 1996-02-07 1999-01-14 Sanol Arznei Schwarz Gmbh Verwendung gasdichter Primärpackmittel für pharmazeutische Zusammensetzungen
DE19726812A1 (de) * 1997-06-25 1999-01-07 Isis Pharma Gmbh Neue Derivate des Pentaerythrits, deren Herstellung und Verwendung sowie Intermediate zur Synthese derselben
US5958926A (en) * 1996-11-01 1999-09-28 Nitromed, Inc. Nitrosated and nitrosylated phosphodiesterase inhibitor compounds, compositions and their uses
US6331543B1 (en) 1996-11-01 2001-12-18 Nitromed, Inc. Nitrosated and nitrosylated phosphodiesterase inhibitors, compositions and methods of use
USRE37234E1 (en) 1996-11-01 2001-06-19 Nitromed, Inc. Nitrosated and nitrosylated phosphodiestrase inhibitor compounds, compositions and their uses
ZA989356B (en) * 1997-10-16 1998-11-16 Isis Pharma Gmbh Pharmaceutical preparations
DE19745622A1 (de) * 1997-10-16 1999-04-22 Isis Pharma Gmbh Neue Salpetersäureester des Pentaerythrits
DE69830069T3 (de) * 1997-10-17 2012-02-09 Ark Therapeutics Ltd. Verwendung von hemmern des renin-angiotensin systems zur behandlung von hypoxie oder verringertem stoffwechsel
US6472425B1 (en) 1997-10-31 2002-10-29 Nitromed, Inc. Methods for treating female sexual dysfunctions
EP1087926A2 (de) * 1998-06-24 2001-04-04 Alpharma-Isis GmbH & Co. KG Analytische substrate und antioxidative mittel
US6465463B1 (en) 1999-09-08 2002-10-15 Nitromed, Inc. Methods of treating and preventing congestive heart failure with hydralazine compounds and isosorbide dinitrate or isosorbide mononitrate
US7235237B2 (en) 1999-10-29 2007-06-26 Nitromed, Inc. Methods of treating vascular diseases characterized by nitric oxide insufficiency
US7708989B2 (en) 1999-10-29 2010-05-04 Nitromed, Inc. Methods of treating vascular diseases characterized by nitric oxide insufficiency
US7537785B2 (en) 1999-10-29 2009-05-26 Nitromed, Inc. Composition for treating vascular diseases characterized by nitric oxide insufficiency
WO2001035961A1 (en) 1999-10-29 2001-05-25 Nitromed, Inc. Methods of treating vascular diseases characterized by nitric oxide insufficiency
ES2258365B1 (es) * 2003-10-03 2007-12-01 Lacer, S.A. Derivados de disulfuro, sulfuro, sulfoxido y sulfona de azucares ciclicos y sus usos.
WO2008124505A2 (en) * 2007-04-05 2008-10-16 Ironwood Pharmaceuticals,Inc. Soluble guanylate cyclase (sgc) modulators for treatment of lipid related disorders
MA34330B1 (fr) * 2010-05-27 2013-06-01 Merck Sharp & Dohme Activateurs de guanylate cyclase soluble
RU2467748C1 (ru) * 2011-08-08 2012-11-27 Федеральное государственное автономное образовательное учреждение высшего профессионального образования "Белгородский государственный национальный исследовательский университет" Производное 3-(2,2,2-триметилгидразиний)пропионата - глицинат 3-(2,2,2-триметилгидразиний)пропионат калия, обладающее эндотелиопротекторной активностью
JP5360939B2 (ja) * 2011-09-28 2013-12-04 国立大学法人徳島大学 ニトロソニフェジピン誘導体を有効成分とする動脈硬化症治療剤

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR984523A (fr) * 1949-02-10 1951-07-06 Phosphate de trinitro-triéthanolamine et procédé de préparation
DE1695897C3 (de) * 1966-07-04 1979-02-15 Takeda Chemical Industries Ltd N-Acyl-sydnonimine, deren Salze, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel
AU465217B2 (en) * 1971-04-29 1975-09-18 American Home Products Corporation Mononitrte esters of 1,4:3, 6-dianhydro-d-glucitol
US3886186A (en) * 1971-04-29 1975-05-27 American Home Prod Mononitrate esters of 1,4:3,6-dianhydro-d-glucitol
DE2532124C3 (de) * 1975-07-18 1979-04-19 Cassella Ag, 6000 Frankfurt Verfahren zur Herstellung von 4-Amino-morpholin
US4200640A (en) * 1976-04-02 1980-04-29 Chugai Seiyaku Kabushiki Kaisha Nitric ester of N-(2-hydroxyethyl)nicotinamide and pharmaceutical use
DE2623800C3 (de) * 1976-05-28 1978-11-23 Sanol Schwarz-Monheim Gmbh, 4000 Duesseldorf Obersättigte wässerige Isosorbiddinitrat-Lösung, Herstellungsverfahren und Verwendung
US4065488A (en) * 1977-02-24 1977-12-27 American Home Products Corporation Process for preparing 1,4:3,6-dianhydro-D-glucitol 2-nitrate
DE2903927C2 (de) * 1979-02-02 1981-03-12 Sanol Schwarz-Monheim Gmbh, 4019 Monheim Verfahren zur selektiven Herstellung von Isosorbid-5-nitrat
DE3028873C2 (de) * 1980-07-30 1983-10-27 Boehringer Mannheim Gmbh, 6800 Mannheim Verfahren zur Herstellung von 1,4 zu 3,6-Dianhydro-D-glucit-5-nitrat (Isosorbid-5-nitrat)
DE3102947A1 (de) * 1981-01-29 1982-09-02 Heinrich Mack Nachf., 7918 Illertissen Verfahren zur herstellung von isosorbid-5-nitrat
FR2500835A1 (fr) * 1981-02-27 1982-09-03 Poudres & Explosifs Ste Nale Procede de synthese des mononitrates d'isosorbide
DE3117612A1 (de) * 1981-05-05 1982-11-25 Cassella Ag, 6000 Frankfurt Verfahren zur herstellung von isosorbid-5-nitrat
DE3124410A1 (de) * 1981-06-22 1983-01-05 Heinrich Mack Nachf., 7918 Illertissen Verfahren zur herstellung von isosorbid-2-nitrat
JPS5910513A (ja) * 1982-07-12 1984-01-20 Nitto Electric Ind Co Ltd 医薬製剤
DE3325652A1 (de) * 1983-07-15 1985-01-24 Dr. Rentschler Arzneimittel Gmbh & Co, 7958 Laupheim Feste, stabile isosorbid-5-mononitrat enthaltende arzneimittelzubereitungen und verfahren zu ihrer herstellung
DE3328094A1 (de) * 1983-08-04 1985-02-21 H. Trommsdorff GmbH & Co, 5110 Alsdorf Phlegmatisierte pharmazeutische zubereitung von explosionsfaehigen salpetersaeureestern
DE3479800D1 (en) * 1983-11-25 1989-10-26 Toshin Chemical Co A method for the preparation of isosorbide-5-nitrate and sodium isosorbide-5-nitrate hydrate as a precursor thereof
DD244980A1 (de) * 1985-12-18 1987-04-22 Isis Chemie Zwickau Veb Verfahren zur herstellung von n-morpholinoaminoacetonitril und dessen hydrochlorid
DD293492A5 (de) * 1987-11-26 1991-09-05 Isis-Chemie Gmbh,De Verfahren zur herstellung einer glyceroltrinitrat-arzneiform mit gleichmaessig verzoegerter arzneistofffreisetzung
US5284872A (en) * 1989-09-12 1994-02-08 Schwarz Pharma Ag Nitrato alkanoic acid derivatives, methods for their production, pharmaceutical compositions containing the derivatives and medicinal uses thereof
DE4007705C1 (es) * 1990-03-10 1991-09-26 G. Pohl-Boskamp Gmbh & Co. Chemisch-Pharmazeutische Fabrik, 2214 Hohenlockstedt, De
DE4038203A1 (de) * 1990-11-30 1992-06-04 Kali Chemie Pharma Gmbh Pharmazeutische spray-zubereitungen mit coronaraktiven wirkstoffen
US5385937A (en) * 1991-04-10 1995-01-31 Brigham & Women's Hospital Nitrosation of homocysteine as a method for treating homocysteinemia

Also Published As

Publication number Publication date
IS4365A (is) 1996-09-25
AU2134595A (en) 1995-10-23
LT96148A (en) 1997-12-29
NO964102L (no) 1996-09-27
EE9600139A (et) 1997-04-15
CA2186783A1 (en) 1995-10-12
DE4410997A1 (de) 1995-10-26
SK121896A3 (en) 1998-10-07
CZ283696A3 (cs) 1998-03-18
EP0752858A1 (de) 1997-01-15
PL316528A1 (en) 1997-01-20
HU220165B (hu) 2001-11-28
LV11666A (lv) 1997-02-20
NO964102D0 (no) 1996-09-27
HU9602671D0 (en) 1996-11-28
JPH09510979A (ja) 1997-11-04
FI963883A0 (fi) 1996-09-27
LV11666B (en) 1997-06-20
DE19580261D2 (de) 1997-05-28
LT4310B (lt) 1998-03-25
BG100930A (en) 1997-07-31
BG63073B1 (bg) 2001-03-30
CN1150387A (zh) 1997-05-21
FI963883A (fi) 1996-09-27
HUT76676A (en) 1997-10-28
WO1995026725A1 (de) 1995-10-12
SI9520047A (en) 1997-06-30
AU698359B2 (en) 1998-10-29

Similar Documents

Publication Publication Date Title
MX9604434A (es) Productos farmaceuticos y medicamentos para la prevencion y el tratamiento de disfunciones endoteliales.
UA39158C2 (uk) Похідні n4-оксикарбоніл-5'-дезокси-5-фторцитидину та фармацевтичний препарат на їх основі
IL127244A (en) Substituted amines, methods of their preparation and pharmaceutical compositions containing them
GEP20033025B (en) 4,4-Biarylpiperidine Derivatives with Opioid Receptor Activity
IL94990A0 (en) Pharmaceutical compositions for the prophylaxis and/or treatment of prostatic diseases
TR199903280T2 (xx) Sertralin tuzlar� ve sertralinin tutmal�-bo�altma dozaj bi�imleri.
MY106407A (en) N-(3-hydroxy-4-piperidinyl)(dihydrobenzo-furan, dihydro-2h-benzopyran or dihydro-benzodioxin) carboxamide derivatives.
CA2041260A1 (en) Ultrasonic contrast agents, processes for their preparation and the use thereof as diagnostic and therapeutic agents
HUP9803018A3 (en) Use of cyclooxygenase-2 inhibitors for producing pharmaceutical compositions suitable for the treatment and prevention of tumors, tumor-veloted disorders and cachexia
BG102999A (en) New 2,3-diasubstituted-4-(3h)-quinazolinons
BG104599A (en) Inhibition of raf kinase using symmetrical and unsymmetrical substituted diphenyl ureas
NZ334124A (en) Use of the chelating agent clioquinol, with vitamin B12 for the manufacture of a pharmaceutical composition for the treatment of alzheimer's disease
BG101118A (en) Therapeutical compounds
CA2200195A1 (en) Use of aromatase inhibitors for the production of a pharmaceutical agentfor treating a relative androgen deficiency in men
ZA922297B (en) Crystalline tiababine monohydrate,its preparation and use
TW200640944A (en) VGF polypeptides and methods of treating VGF-related disorders
EP1032556A4 (en) PHARMACEUTICALLY EFFECTIVE COMPOUNDS AND METHODS OF THEIR APPLICATION
SE9604348D0 (sv) Användning av hydroxyguanidiner
MY128260A (en) Cyclopentane-and-pentene-b-amino acids
IL126235A (en) Compounds with growth hormone releasing properties, pharmaceutical compositions comprising them and their use
CA2441192A1 (en) The use of lysine for the prevention or treatment of stress-induced diseases
MXPA02000680A (es) Polipeptidos vgf y metodos para tratar desordenes relacionados con vgf.
GB9509888D0 (en) Terpenoidic derivatives useful as antitumour agents
ZA923935B (en) New 2-amino-5-cyano-1,4-dihydropyridines,processes for their preparation and their use in medicaments
EP0604853A3 (en) Pharmaceutical composition for preventing or treating arteriosclerosis.

Legal Events

Date Code Title Description
FG Grant or registration
MM Annulment or lapse due to non-payment of fees